CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a ...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Ruihao Huang, Qin Wen and Xi Zhang Tags: Correspondence Source Type: research
More News: Cancer & Oncology | Hematology